Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Mechanism that allows bacteria to infect plants may inspire cure for eye disease

05.08.2013
By borrowing a tool from bacteria that infect plants, scientists have developed a new approach to eliminate mutated DNA inside mitochondria—the energy factories within cells.

Doctors might someday use the approach to treat a variety of mitochondrial diseases, including the degenerative eye disease Leber hereditary optic neuropathy (LHON). The research, published online today in Nature Medicine, was funded by the National Eye Institute (NEI), a part of the National Institutes of Health (NIH).

Mitochondria convert fuel from food into a form of energy that cells can use. They also make enzymes for a variety of cell functions, and in humans they are the only cell component other than the nucleus that houses genes. Mitochondrial gene mutations can lead to a variety of health problems including muscle weakness, heart disease, and blindness in the case of LHON. Most cells contain thousands of mitochondrial DNA (mtDNA) copies. People with mitochondrial disease often have both mutant and normal mtDNA within their cells. No cures exist for mitochondrial diseases and few effective treatments are available.

Searching for strategies to repair mitochondrial gene defects, a group of investigators at the University of Miami Miller School of Medicine explored proteins called transcription activator-like (TAL) effectors. In nature, TAL effectors are found only in certain types of plant-infecting bacteria. They enable the bacteria to use plant DNA to multiply and spread infection.

Scientists recently began using TAL effectors to modify DNA in a variety of organisms. In the lab, TAL effectors can be fused with DNA-breaking proteins called nucleases. These TAL effector nucleases (TALENs) can be used to add or remove specific genes or correct gene mutations—techniques that fall under the broad category of genome editing. During the past few years, scientists have begun adapting TALENs and other genome-editing tools for gene therapy. Until now, scientists had only used TALENs to edit genes in the cell nucleus. Today's report marks the first time TALENs have been used to edit mitochondrial genes.

"Mitochondrial-targeted TALENS (mitoTALENs) represent the most promising hope for an effective treatment of diseases caused by mutations in mtDNA," said Carlos T. Moraes, Ph.D., a professor of neurology and cell biology at the University of Miami Miller School of Medicine and principal investigator of the study. "Our research demonstrates that mitoTALENs can substantially decrease or eliminate mutant mtDNA without harming normal mtDNA."

Using cells in the lab, the investigators designed mitoTALENs to bind and cut mitochondrial DNA that had a specific mutation in the gene Complex I, which causes LHON. The scientists then tested whether the mitoTALENs eliminated the mutant mtDNA.

Analysis revealed a temporary drop in cells' total mtDNA, which was due to a reduction in mutant mtDNA. "Once the mitoTALENs bound and cut the DNA at the specified target, the mutant mtDNA was degraded," said Moraes. "The drop in total mtDNA stimulated the cells to increase their mtDNA by replicating the unaffected molecules. Two weeks later, mtDNA levels had returned to normal. But since the mutant mtDNA was destroyed, the cells had mostly normal mtDNA."

Reducing but not necessarily eliminating all mutant mtDNA from a person's cells would be sufficient to treat many mitochondrial diseases, Moraes said. Mutant mtDNA typically does not cause signs of disease until it makes up 80 percent or more of the total mtDNA in a cell, which helps explain why age of onset, the constellation of symptoms, and disease severity varies among individuals with the same mutation. "A modest reduction in mutant mtDNA is likely sufficient to effectively treat disease," he said.

"The science in this project advances an imaginative and very clever approach that may one day lead to a therapeutic strategy for mitochondrial diseases," said Houmam Araj, Ph.D., director of the lens/cataract and oculomotor/neuro-ophthalmology programs at the NEI.

Symptoms of LHON include an abrupt loss of central vision at about age 20 in one eye followed shortly thereafter by the other eye. Although a variety of gene mutations are linked to the disease, most cases involve Complex I mutations, which cause degeneration of the nerves in the back of the eye that transmit visual information to the brain. Neurological problems such as tremors may also occur.

Getting mitoTALENs into cells in tissues presents a formidable challenge, however. The scientists plan next to test the approach in animals.

Additional Miller School members of the research team included Siôn L. Williams, Ph.D., Sandra R. Bacman, Ph.D., Milena Pinto, Ph.D., and Susana Peralta, Ph.D.

The research was supported in part by the National Eye Institute (EY010804), the National Institute on Aging (AG036871), and the National Institute of Neurological Disorders and Stroke (NS079965).

Reference: Bacman SR, et al. Specific elimination of mutant mitochondrial genomes in patient-derived cells by mitoTALENs. Nature Medicine. Published online Aug. 4, 2013. http://dx.doi.org/10.1038/nm.3261.

The National Eye Institute, part of the National Institutes of Health, leads the federal government's research on the visual system and eye diseases. NEI supports basic and clinical science programs that result in the development of sight-saving treatments. For more information, visit http://www.nei.nih.gov.

About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit http://www.nih.gov.

NIH...Turning Discovery Into Health®

Dustin Hays | EurekAlert!
Further information:
http://www.nei.nih.gov
http://www.nih.gov

More articles from Health and Medicine:

nachricht NTU scientists build new ultrasound device using 3-D printing technology
07.12.2016 | Nanyang Technological University

nachricht How to turn white fat brown
07.12.2016 | University of Pennsylvania School of Medicine

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Significantly more productivity in USP lasers

In recent years, lasers with ultrashort pulses (USP) down to the femtosecond range have become established on an industrial scale. They could advance some applications with the much-lauded “cold ablation” – if that meant they would then achieve more throughput. A new generation of process engineering that will address this issue in particular will be discussed at the “4th UKP Workshop – Ultrafast Laser Technology” in April 2017.

Even back in the 1990s, scientists were comparing materials processing with nanosecond, picosecond and femtosesecond pulses. The result was surprising:...

Im Focus: Shape matters when light meets atom

Mapping the interaction of a single atom with a single photon may inform design of quantum devices

Have you ever wondered how you see the world? Vision is about photons of light, which are packets of energy, interacting with the atoms or molecules in what...

Im Focus: Novel silicon etching technique crafts 3-D gradient refractive index micro-optics

A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.

Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...

Im Focus: Quantum Particles Form Droplets

In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.

“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...

Im Focus: MADMAX: Max Planck Institute for Physics takes up axion research

The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.

The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ICTM Conference 2017: Production technology for turbomachine manufacturing of the future

16.11.2016 | Event News

Innovation Day Laser Technology – Laser Additive Manufacturing

01.11.2016 | Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

 
Latest News

NTU scientists build new ultrasound device using 3-D printing technology

07.12.2016 | Health and Medicine

The balancing act: An enzyme that links endocytosis to membrane recycling

07.12.2016 | Life Sciences

How to turn white fat brown

07.12.2016 | Health and Medicine

VideoLinks
B2B-VideoLinks
More VideoLinks >>>